Salud financiera de hoja de balance de Jubilant Pharmova
Salud financiera controles de criterios 4/6
Jubilant Pharmova tiene un patrimonio de accionistas total de ₹59.3B y una deuda total de ₹28.3B, lo que sitúa su ratio deuda-patrimonio en 47.7%. Sus activos y pasivos totales son ₹119.2B y ₹60.0B respectivamente. El BAIT de Jubilant Pharmova es de ₹6.6B, por lo que su ratio de cobertura de intereses es de 2.8. Tiene efectivo e inversiones a corto plazo que ascienden a ₹10.8B.
Información clave
47.7%
Ratio deuda-patrimonio
₹28.25b
Deuda
| Ratio de cobertura de intereses | 2.8x |
| Efectivo | ₹10.77b |
| Patrimonio | ₹59.27b |
| Total pasivo | ₹59.97b |
| Activos totales | ₹119.24b |
Actualizaciones recientes sobre salud financiera
Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet
Nov 15
Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet
Jul 13Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet
Mar 14These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively
Dec 02These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively
Jul 26Is Jubilant Pharmova (NSE:JUBLPHARMA) A Risky Investment?
Dec 10Recent updates
Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet
Nov 15A Look At The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
Oct 27Jubilant Pharmova Limited (NSE:JUBLPHARMA) Surges 25% Yet Its Low P/S Is No Reason For Excitement
Aug 24Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet
Jul 13Jubilant Pharmova (NSE:JUBLPHARMA) Has A Somewhat Strained Balance Sheet
Mar 14Jubilant Pharmova Limited (NSE:JUBLPHARMA) Shares Fly 27% But Investors Aren't Buying For Growth
Dec 23These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively
Dec 02These 4 Measures Indicate That Jubilant Pharmova (NSE:JUBLPHARMA) Is Using Debt Extensively
Jul 26Estimating The Fair Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
May 11Is Jubilant Pharmova (NSE:JUBLPHARMA) A Risky Investment?
Dec 10Jubilant Pharmova (NSE:JUBLPHARMA) Has Announced A Dividend Of ₹5.00
Aug 01Does Jubilant Pharmova (NSE:JUBLPHARMA) Have A Healthy Balance Sheet?
Jun 15Calculating The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
Mar 22Is Jubilant Pharmova (NSE:JUBLPHARMA) A Risky Investment?
Feb 15Calculating The Intrinsic Value Of Jubilant Pharmova Limited (NSE:JUBLPHARMA)
Dec 20Here's Why It's Unlikely That Jubilant Pharmova Limited's (NSE:JUBLPHARMA) CEO Will See A Pay Rise This Year
Sep 15Here's Why Jubilant Pharmova (NSE:JUBLPHARMA) Can Manage Its Debt Responsibly
Aug 21Time To Worry? Analysts Are Downgrading Their Jubilant Pharmova Limited (NSE:JUBLPHARMA) Outlook
Jun 08An Intrinsic Calculation For Jubilant Pharmova Limited (NSE:JUBLPHARMA) Suggests It's 39% Undervalued
May 25Analysts Just Made A Major Revision To Their Jubilant Pharmova Limited (NSE:JUBILANT) Revenue Forecasts
Feb 10Estimating The Fair Value Of Jubilant Pharmova Limited (NSE:JUBILANT)
Feb 08
Análisis de la situación financiera
Pasivos a corto plazo: Los activos a corto plazo (₹35.0B) de JUBLPHARMA superan a sus pasivos a corto plazo (₹19.5B).
Pasivo a largo plazo: Los activos a corto plazo (₹35.0B) de JUBLPHARMA no cubren sus pasivos a largo plazo (₹40.5B).
Historial y análisis de deuda-patrimonio
Nivel de deuda: El ratio deuda neta-patrimonio (29.5%) de JUBLPHARMA se considera satisfactorio.
Reducción de la deuda: El ratio deuda-patrimonio de JUBLPHARMA ha pasado de 85.8% a 47.7% en los últimos 5 años.
Cobertura de la deuda: La deuda de JUBLPHARMA está bien cubierta por el flujo de caja operativo (27.2%).
Cobertura de intereses: Los pagos de intereses de la deuda de JUBLPHARMA no están bien cubiertos por el BAIT (2.8x cobertura).